vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Bumble Inc. (BMBL). Click either name above to swap in a different company.

Bumble Inc. is the larger business by last-quarter revenue ($212.4M vs $191.2M, roughly 1.1× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -14.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -11.1%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Bumble is a mobile app for online dating and social networking. It was founded by Whitney Wolfe Herd and was launched in December 2014. Bumble is operated by Bumble Inc., which also owns Badoo.

AXSM vs BMBL — Head-to-Head

Bigger by revenue
BMBL
BMBL
1.1× larger
BMBL
$212.4M
$191.2M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+71.5% gap
AXSM
57.4%
-14.1%
BMBL
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
48.1%
-11.1%
BMBL

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AXSM
AXSM
BMBL
BMBL
Revenue
$191.2M
$212.4M
Net Profit
$52.6M
Gross Margin
74.2%
Operating Margin
-33.1%
30.7%
Net Margin
24.8%
Revenue YoY
57.4%
-14.1%
Net Profit YoY
236.3%
EPS (diluted)
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
BMBL
BMBL
Q1 26
$191.2M
$212.4M
Q4 25
$196.0M
$224.2M
Q3 25
$171.0M
$246.2M
Q2 25
$150.0M
$248.2M
Q1 25
$121.5M
$247.1M
Q4 24
$118.8M
$261.6M
Q3 24
$104.8M
$273.6M
Q2 24
$87.2M
$268.6M
Net Profit
AXSM
AXSM
BMBL
BMBL
Q1 26
$52.6M
Q4 25
$-28.6M
$-490.2M
Q3 25
$-47.2M
$37.3M
Q2 25
$-48.0M
$-253.7M
Q1 25
$-59.4M
$13.4M
Q4 24
$-74.9M
$4.2M
Q3 24
$-64.6M
$-613.2M
Q2 24
$-79.3M
$27.4M
Gross Margin
AXSM
AXSM
BMBL
BMBL
Q1 26
74.2%
Q4 25
71.2%
Q3 25
71.9%
Q2 25
70.1%
Q1 25
70.3%
Q4 24
Q3 24
Q2 24
Operating Margin
AXSM
AXSM
BMBL
BMBL
Q1 26
-33.1%
30.7%
Q4 25
-13.8%
-256.8%
Q3 25
-27.0%
25.9%
Q2 25
-24.5%
-136.3%
Q1 25
-46.9%
18.1%
Q4 24
-61.1%
14.1%
Q3 24
-59.8%
-306.3%
Q2 24
-89.5%
19.3%
Net Margin
AXSM
AXSM
BMBL
BMBL
Q1 26
24.8%
Q4 25
-14.6%
-218.7%
Q3 25
-27.6%
15.2%
Q2 25
-32.0%
-102.2%
Q1 25
-48.9%
5.4%
Q4 24
-63.1%
1.6%
Q3 24
-61.7%
-224.1%
Q2 24
-91.0%
10.2%
EPS (diluted)
AXSM
AXSM
BMBL
BMBL
Q1 26
$0.34
Q4 25
$-0.55
$-3.96
Q3 25
$-0.94
$0.33
Q2 25
$-0.97
$-2.45
Q1 25
$-1.22
$0.13
Q4 24
$-1.54
$0.09
Q3 24
$-1.34
$-5.11
Q2 24
$-1.67
$0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
BMBL
BMBL
Cash + ST InvestmentsLiquidity on hand
$305.1M
$245.6M
Total DebtLower is stronger
$70.0M
Stockholders' EquityBook value
$735.2M
Total Assets
$713.6M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
BMBL
BMBL
Q1 26
$305.1M
$245.6M
Q4 25
$322.9M
$175.8M
Q3 25
$325.3M
$307.9M
Q2 25
$303.0M
$261.7M
Q1 25
$300.9M
$202.2M
Q4 24
$315.4M
$204.3M
Q3 24
$327.3M
$252.1M
Q2 24
$315.7M
$286.7M
Total Debt
AXSM
AXSM
BMBL
BMBL
Q1 26
$70.0M
Q4 25
$590.6M
Q3 25
Q2 25
Q1 25
Q4 24
$621.3M
Q3 24
Q2 24
Stockholders' Equity
AXSM
AXSM
BMBL
BMBL
Q1 26
$735.2M
Q4 25
$88.3M
$570.0M
Q3 25
$73.7M
$675.5M
Q2 25
$73.1M
$577.6M
Q1 25
$53.2M
$814.5M
Q4 24
$57.0M
$824.5M
Q3 24
$92.9M
$852.6M
Q2 24
$102.9M
$1.7B
Total Assets
AXSM
AXSM
BMBL
BMBL
Q1 26
$713.6M
$1.5B
Q4 25
$689.8M
$1.4B
Q3 25
$669.3M
$2.2B
Q2 25
$639.8M
$2.2B
Q1 25
$596.7M
$2.5B
Q4 24
$568.5M
$2.5B
Q3 24
$561.5M
$2.6B
Q2 24
$548.2M
$3.5B
Debt / Equity
AXSM
AXSM
BMBL
BMBL
Q1 26
Q4 25
1.04×
Q3 25
Q2 25
Q1 25
Q4 24
0.75×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
BMBL
BMBL
Operating Cash FlowLast quarter
$77.2M
Free Cash FlowOCF − Capex
$73.8M
FCF MarginFCF / Revenue
34.8%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
BMBL
BMBL
Q1 26
$77.2M
Q4 25
$-18.7M
$59.1M
Q3 25
$1.0M
$76.8M
Q2 25
$-32.4M
$71.2M
Q1 25
$-43.4M
$43.2M
Q4 24
$-26.2M
$-5.4M
Q3 24
$-18.6M
$93.5M
Q2 24
$-30.1M
$32.9M
Free Cash Flow
AXSM
AXSM
BMBL
BMBL
Q1 26
$73.8M
Q4 25
$-18.7M
Q3 25
$988.0K
Q2 25
$-32.4M
Q1 25
$-43.7M
Q4 24
$-26.2M
Q3 24
$-18.7M
Q2 24
$-30.2M
FCF Margin
AXSM
AXSM
BMBL
BMBL
Q1 26
34.8%
Q4 25
-9.6%
Q3 25
0.6%
Q2 25
-21.6%
Q1 25
-36.0%
Q4 24
-22.1%
Q3 24
-17.9%
Q2 24
-34.6%
Capex Intensity
AXSM
AXSM
BMBL
BMBL
Q1 26
1.6%
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.3%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
AXSM
AXSM
BMBL
BMBL
Q1 26
1.47×
Q4 25
Q3 25
2.06×
Q2 25
Q1 25
3.22×
Q4 24
-1.29×
Q3 24
Q2 24
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Product sales, net$189.4M99%
Royalty revenue and milestone revenue$1.8M1%

BMBL
BMBL

Segment breakdown not available.

Related Comparisons